Haemophilus influenzae b Antibody, IgG
Also known as: HIBE IGG
Use
This test is used to evaluate the ability of a patient to produce antibody to a protein conjugated bacterial (H. influenza) vaccine, which can help rule out antibody deficiency. Responder status is assessed based on the ratio of post-vaccination concentration to pre-vaccination concentration of Haemophilus influenza b antibody, IgG, determining whether a patient is a good responder, weak responder, or non-responder.
Special Instructions
Not provided.
Limitations
This test has not been approved by the US Food and Drug Administration but is performed in a CLIA certified laboratory for clinical purposes. Therefore, its performance characteristics were determined by ARUP Laboratories.
New York Approved
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
Haemophilus influenzae b Antibody, IgG
Protein
LOINC Codes
- 11256-5 - Haem influ B IgG Ser-mCnc
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.15 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Separate serum from cells ASAP or within 2 hours of collection. Transfer to ARUP Standard Transport Tube and mark specimens clearly as 'Pre-Vaccine' or 'Post-Vaccine'.
Storage Instructions
Refrigerated
Causes for Rejection
Plasma or other body fluids. Contaminated, hemolyzed, or severely lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year (avoid repeated freeze/thaw cycles) |
Other tests from different labs that may be relevant